Interview with Marcin Hanczaruk, General Manager, Ferring Pharmaceuticals Poland
As we are just entering 2011, could you share with us the results of the Polish affiliate in 2010? 2010 was for Ferring Poland a year of reconstruction. The affiliate…
Address: ul. Bonifraterska 17
00-203 Warszawa
Poland
Tel: +48 22 246 0680
Ferring Pharmaceuticals is a research-driven biopharmaceutical company devoted to identifying, developing and marketing innovative products in the fields of reproductive health, urology, gastroenterology, endocrinology and osteoarthritis.
The company’s research activities and products are connected by a common thread focused on the provision of tailored treatments that work on the body’s own terms to enable doctors to combat numerous diseases and medical conditions.
The company has gained international recognition over the last 20 years for the creation of inventive medications that improve the quality of life of children and adults all around the world.
Ferring has its own production facilities in several European countries, in South America, Israel and China. With the acquisition of Bio-Technology General in 2005, it has capabilities in recombinant biotechnology as well as more traditional pharmaceutical manufacturing.
Ferring’s marketing, medical services and sales teams, led by corporate headquarters in Saint-Prex, Switzerland, operate from more than 45 countries and employ more than 3700 people throughout the world, while treatments are available in more than 70 countries. This expansion has allowed Ferring to maintain a double digit annual growth rate over the last two decades.
Ferring’s R&D projects complement Ferring’s product portfolio and will add a new generation of products to some of the company’s most successful specialty brands. R&D facilities are located in Denmark, Israel and California, USA.
Ferring is committed to a future where it will continue to provide new and innovative medicines by utilising existing and acquired skills and the development of pioneering technologies and, where necessary, through partnerships with academic institutes and other companies.
For fifty years, we have been at the forefront of innovation in the field of naturally occurring human peptides. We have developed treatments in areas that span the human life cycle, including: reproductive health, endocrinology, gastroenterology and urology:
Ferring’s infertility treatments give infertile couples the chance to have babies
In obstetrics, Ferring helps premature children to be born healthy and without handicaps
With treatments in endocrinology, Ferring gives children the chance to overcome growth deficiencies
Ferring’s inflammatory bowel disease (IBD) treatments enable young adults with IBD to live a normal life
In urology, Ferring’s treatment for nocturia and bedwetting helps adults and children to an undisturbed night’s sleep
Ferring’s testosterone replacement treatment improves the key symptoms of low testosterone, reduces fat and improves muscle strength and mood
Ferring’s hormonal therapy for prostate cancer offers a new treatment option to men with an advanced hormone-dependent cancer
Ferring’s strength is our extensive knowledge of peptides and the role they play in the human body.
As we are just entering 2011, could you share with us the results of the Polish affiliate in 2010? 2010 was for Ferring Poland a year of reconstruction. The affiliate…
“Innovation is about bringing new chemical compounds on the market; but it is also, and sometimes even more, to continue the therapeutic development of the drugs which are already there”…
Merck’s managing director discusses the importance of diversification to succeed in Poland by saying: “Nowadays, in such a dynamic environment the healthy level of diversification that Merck offers is becoming…
Medtronic’s country director brings some interesting perspectives on the differences between the pharma and medical device regulations in Poland by saying: “the medical device industry is discriminated against, as we…
The founder of PBA Consultancy offers a critical analysis of the new Reimbursement Act, looking at what could still be done to improve the system. Could you give us the…
The founder of PBA Consultancy offers a critical analysis of the new Reimbursement Act, looking at what could still be done to improve the system. Could you give us the…
The founder of PBA Consultancy offers a critical analysis of the new Reimbursement Act, looking at what could still be done to improve the system. Could you give us the…
Poland’s Main Pharmaceutical Inspector discusses the dangers behind falsified medicines and the need to control internet pharmacies. She also showcases the great power Poland holds as a manufacturing country with…
“In this very competitive environment, patents give companies an edge; this is why we must maintain innovative breakthroughs in our industry. This will then allow us to compete more efficiently…
“The overall Polish healthcare system is quite good. Of course, there are flaws, but Poland is equipped to treat almost any disease. The flaws in the system stem from historically…
In a world where diabetes increasingly more common, Poland has not been spared, with 2.5 million diabetic patients currently, and with a further 750,000 still unaware of their condition. In…
Cezary Sledziewski, Executive Director of PZPPF, discusses the pros and cons of Poland’s catching up with EU’s rising standards. He argues: “No one currently knows exactly how much these costs…
Polpharma , Poland’s role model and largest Polish manufacturer of drug products and active pharmaceutical ingredients, has pushed the Polish boundaries with the objective to become the fastest growing regional…
See our Cookie Privacy Policy Here